iSTAR Medical announces € 40 million Series C financing

To accelerate development and commercialisation of innovative Glaucoma MIGS device, MINIjectTM Wavre, Belgium: 5 September 2019 —iSTAR Medical SA, a private medical device company developing novel ophthalmic implants for the treatment of glaucoma, today announced the completion of a € 40 million Series C financing. The financing was led by healthcare specialist funds LSP and Gimv, with participation by Earlybird and BNP Paribas Fortis Private Equity. Existing shareholders including Capricorn Partners, Walloon Region Investment Fund (SRIW) and Belgian Federal Investment Fund (SFPI‐FPIM) also participated. This financing will support the development of iSTAR Medical’s MINIjectTM device along the path to commercialisation in Europe and the United States. Glauchttps://lindacare.com/newsoma is the second leading cause of adult blindness globally affecting more than 92 million people. Micro-invasive glaucoma surgery (MIGS) is the most promising and fastest-growing therapeutic option in the treatment of glaucoma.

More info on iSTAR Medical‘s website.